An underlying cancer can be identified in about 73% of patients with CRMP5 antibody associated PNS (5), and CRMP5 antibodies often coexist with other paraneoplastic antibodies, most commonly anti-Hu (3, 4). This evidence concerns the gene DPYSL5 and cancer.